Metropolitan Life Insurance CO Viridian Therapeutics, Inc.\De Transaction History

Metropolitan Life Insurance CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$17.09 - $23.82 $905 - $1,262	-53 Reduced 1.97%	2,632 $46,000
Q3 2023 Nov 14, 2023	BUY	$15.16 - $24.7 $5,715 - $9,311	377 Added 16.33%	2,685 $41,000
Q2 2023 Aug 10, 2023	BUY	$22.57 - $29.67 $5,890 - $7,743	261 Added 12.75%	2,308 $54,000
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $7,336 - $11,016	-293 Reduced 12.52%	2,047 $52,000
Q4 2022 Jun 14, 2023	BUY	$18.78 - $29.74 $5,502 - $8,713	293 Added 14.31%	2,340 $68.4 Million
Q4 2022 Mar 30, 2023	BUY	$18.78 - $29.74 $14,047 - $22,245	748 Added 46.98%	2,340 $68,000
Q4 2022 Feb 15, 2023	BUY	$18.78 - $29.74 $14,047 - $22,245	748 Added 46.98%	2,340 $68,000
Q3 2022 Jun 14, 2023	SELL	$10.7 - $25.5 $4,868 - $11,602	-455 Reduced 22.23%	1,592 $32.7 Million
Q2 2022 Jun 20, 2023	SELL	$9.55 - $19.0 $4,345 - $8,645	-455 Reduced 22.23%	1,592 $18,000
Q2 2022 Mar 30, 2023	SELL	$9.55 - $19.0 $7,143 - $14,212	-748 Reduced 31.97%	1,592 $18,000
Q2 2022 Aug 11, 2022	BUY	$9.55 - $19.0 $15,203 - $30,248	1,592 New	1,592 $18,000

178

76.6M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $759M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.